COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Nature·
- DOI
- 10.1038/s41586-020-2814-7
- PMID
- 32998157
- PMCID
- —
- OpenAlex
- W3090844627
- Study type
- Journal article
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Publication version
This article has a linked preprint
The relationship comes from Crossref version metadata. Compare both records because findings and wording may have changed between versions.
Open linked preprint →Why this research matters now
Early immunogenicity metrics indicate that the formulation triggers complementary defense pathways, positioning it as a candidate tool for future pandemic mitigation strategies pending larger efficacy evaluations.
Structured evidence summary
Research question
The investigation evaluates whether the BNT162b1 nucleoside-modified mRNA candidate can generate measurable humoral and cellular immunity against the SARS-CoV-2 receptor binding domain in adult volunteers.
Study design
Researchers conducted a second phase I/II clinical evaluation utilizing a non-randomized, open-label format following an earlier placebo-controlled assessment.
Population and setting
The trial enrolled healthy individuals between eighteen and fifty-five years old, with geographic context indicated as Germany.
Main findings
Administration of two doses ranging from one to fifty micrograms produced high concentrations of receptor binding domain antibodies and expanded both CD4 and CD8 T cell populations. Serum neutralization capacity reached up to three and a half times the levels observed in previously infected persons, while also covering multiple viral variant forms. The cellular profile demonstrated a predominant TH1 polarization with substantial interferon-gamma secretion.
Public-health relevance
Early immunogenicity metrics indicate that the formulation triggers complementary defense pathways, positioning it as a candidate tool for future pandemic mitigation strategies pending larger efficacy evaluations.
Important limitations
The provided abstract lacks explicit methodological constraints or adverse event reporting. Consequently, this summary is limited to the supplied single-article abstract/metadata and requires the original paper for decision-grade interpretation.
GIDS interpretation
This record documents initial human immunogenicity results for an emerging mRNA platform during the early outbreak phase. It functions as a historical benchmark for understanding developmental timelines and scientific discourse surrounding novel coronavirus countermeasures.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.